Using focused ultrasound to treat prostate cancer while preserving healthy tissue
Transrectal Histotripsy for Focal Ablation of Prostate Cancer
This study is testing a new way to treat prostate cancer using focused ultrasound that aims to destroy cancer cells while keeping healthy tissue safe, helping to reduce side effects like urinary and sexual issues, so patients can feel better during and after treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10930046 on NIH RePORTER |
What this research studies
This research investigates a new method called boiling histotripsy, which uses focused ultrasound to precisely target and destroy prostate cancer cells without harming surrounding healthy tissue. By employing short bursts of ultrasound pulses, the technique aims to minimize side effects commonly associated with traditional prostate cancer treatments, such as urinary and sexual dysfunction. Patients will be monitored using real-time ultrasound imaging to ensure effective treatment delivery. The goal is to improve cancer control while enhancing the quality of life for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with localized prostate cancer who are seeking alternatives to traditional radical treatments.
Not a fit: Patients with advanced prostate cancer or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a less invasive treatment option for prostate cancer that reduces side effects and improves patient quality of life.
How similar studies have performed: While traditional thermal ablation techniques have been used, this novel approach of boiling histotripsy has not been widely tested in clinical settings, making it a potentially groundbreaking method.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Schade, George R — University of Washington
- Study coordinator: Schade, George R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.